Titre : | A proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment (2013) |
Auteurs : | B. VASAE BURDICK ; B. ADINOFF |
Type de document : | Article : Périodique |
Dans : | American Journal of Drug and Alcohol Abuse (Vol.39, n°5, September 2013) |
Article en page(s) : | 291-297 |
Langues: | Anglais |
Discipline : | TRA (Traitement et prise en charge / Treatment and care) |
Mots-clés : |
Thésaurus mots-clés HALLUCINOGENES ; EFFICACITE ; PHARMACOTHERAPIE ; ADDICTION ; TRAITEMENT ; PSILOCYBINE ; RECHERCHE |
Résumé : | Current treatments for addiction are frequently ineffective. Hallucinogenic therapy has been indicated as helpful for a range of substance use disorders, yet this approach remains understudied and publicly unavailable. It is nonetheless a promising treatment, which has significant, long-term beneficial effects with single doses and a profile characterized by general safety, low toxicity, and non-addictiveness. However, pharmacological interventions, such as hallucinogens, should not be offered if the same effects (e.g. psychological insights/mystical experiences) and outcomes (e.g. decreased drug use) could be achieved absent pharmacological intervention. To date, there have been no clinical comparisons of drug-induced altered states with non-drug-induced states for addiction treatment. We propose and then outline a clinical trial to address this gap in knowledge. The proposed design would evaluate abstinence outcomes in a population of prescription opioid abusers after exposure to one of three conditions: a drug-induced altered state using psilocybin, a non-drug-induced altered state via hyperventilation (Holotropic Breathwork), and an active placebo with niacin. The outcomes of such a study would reveal important differences in therapeutic potential by discriminating hallucinogen-dependent effects from those psychological effects resulting from altered states. |
Domaine : | Autres substances / Other substances ; Drogues illicites / Illicit drugs |
Refs biblio. : | 75 |
Affiliation : | Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA |
Accueil